本文選題：熱熔　切入點(diǎn)：定儀　出處：《中國醫(yī)藥工業(yè)雜志》2016年08期

【摘要】：正[Drug Dev Ind Pharm,2016,42(10):1609]采用基團(tuán)貢獻(xiàn)法評價(jià)BCSⅡ類藥物阿瑞匹坦(APR)和載體Soluplus(SOL)的溶解度參數(shù)。通過加熱-冷卻-加熱的差示掃描量熱(DSC)分析評估APR的玻璃化形成能力(glass forming ability,GFA)和玻璃化穩(wěn)定性(glass stability,GS)。根據(jù)物理混合物熔點(diǎn)的下降情況確定熱熔擠出(HME)過程的優(yōu)化溫度。采用動態(tài)濕氣吸附測定儀收集25℃時(shí)的吸附等溫線。
[Abstract]:The solubility parameters of Drug Dev Ind Pharmatorum 422 10: 1609 were evaluated by group contribution method. The glass forming ability of APR was evaluated by means of heat-cooling-heating differential scanning calorimetry (DSCA). The glass-forming ability of APR was evaluated by glass forming capability. The optimum temperature of the hot melt extrusion (HME) process was determined according to the decrease of melting point of the physical mixture. The adsorption isotherms at 25 鈩，

本文編號：1655711